基于小分子药物的体细胞转分化研究进展  

Advances in The Study of Somatic Cell Transdifferentiation Based On Small Molecule Drugs

作　　者：王凯丽 徐希明[1] WANG Kai-li;XU Xi-ming(College of Pharmacy,Jiangsu University,Zhenjiang 212013,China)

机构地区：[1]江苏大学药学院,江苏镇江212013

出　　处：《中国药学杂志》2021年第15期1196-1202,共7页Chinese Pharmaceutical Journal

摘　　要：从核移植开始,细胞重编程依次经历了细胞融合重编程、细胞提取物诱导的重编程、转录因子介导的重编程和小分子药物诱导的重编程。目前,小分子药物诱导的直接重编程得到了广泛的关注和深入的研究。在揭示药物作用机制方面取得了相当大的进展。对小分子直接重编程诱导心肌细胞、神经干细胞、神经元和肝细胞的研究进展作一综述,以期对再生医学方向细胞移植治疗心脏受损、脊髓损伤、肝损伤提供帮助。Starting with the nuclear transplantation,cell reprogramming has in turn gone through cell fusion and cell extract-induced reprogramming,transcription factors-mediated reprogramming,and small molecules-induced reprogramming.To date,small molecular compounds-induced direct reprogramming has gained widespread attention and in-depth research.Considerable progress has been achieved in revealing the mechanisms of drug actions.This article reviews the recent advances in induction of functional myocardial cells,neural stem cells,neurons,and liver cells via small molecules-mediated direct reprogramming.It is expected to provide help for regenerative medicine in the treatment of heart injury,spinal cord injury and liver injury by cell transplantation.

关 键 词：小分子 体细胞 重编程 转分化 

分 类 号：R965[医药卫生—药理学]